Evidence map›Paper›PMID 41104589›Full record

ArticleLiver international : official journal of the International Association for the Study of the Liver2025

Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium.

Lara Buchardt, Viet Loan Dao Thi, Reimar Johne, Mathias Ziersch, Dominik Harms, Jörg Hofmann, Katja Dinkelborg, Mara Klöhn, Mira Choi, Jens Kurreck and 2 more

Abstract read
In one paragraph

Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Update on Hepatitis E Virus Infection 2025: Insights From an International Symposium.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lara BuchardtDepartment of Translational and Computational Infection Research, Ruhr University Bochum, Bochum, Germany.
Viet Loan Dao ThiSchaller Research Group, Department of Infectious Diseases, Virology, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany.
Reimar JohneDepartment of Biological Safety, German Federal Institute of Risk Assessment, Berlin, Germany.
Mathias ZierschDepartment of Applied Biochemistry, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
Dominik HarmsDepartment of Infectious Diseases, Robert Koch Institute, Berlin, Germany.
Jörg HofmannLabor Berlin, Charité-Vivantes GmbH, Berlin, Germany.
Katja DinkelborgTWINCORE, Centre for Experimental and Clinical Infection Research, A Joint Venture Between Helmholtz-Centre for Infection Research and Hannover Medical School, Hannover, Germany.
Mara KlöhnDepartment of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.
Mira ChoiDepartment of Nephrology and Medical Intensive Care, Charité Universitätsmedizin Berlin, Berlin, Germany.ORCID 0000-0002-0286-1491
Jens KurreckDepartment of Applied Biochemistry, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany.
Heiner WedemeyerDepartment of Gastroenterology, Hepatology, Infectious Diseases and Endocrinology, Hannover Medical School, Hannover, Germany.ORCID 0000-0003-2906-0480
Daniel TodtDepartment of Translational and Computational Infection Research, Ruhr University Bochum, Bochum, Germany.ORCID 0000-0002-3564-1014

Funding

Deutsche Forschungsgemeinschaft 551711303Deutsches Zentrum für InfektionsforschungMHH plus Förderstiftung der Medizinischen Hochschule Hannover
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe second Hepatitis E Symposium was held as an integral part of the International DFG/DZIF Joint Meeting on Viral Infections of the Liver and the Heart in Berlin. The symposium aimed to provide a comprehensive exploration of hepatitis E virus (HEV) research and bring together clinicians, basic scientists, public health experts, and bioinformaticians from around the world.

methodsThe program comprised two focused thematic sessions with eight invited speakers presenting recent advances in HEV biology, pathogenesis, and clinical impact. In addition, two interactive round table discussions and two poster sessions facilitated the exchange of recent findings and fostered critical debate.

resultsCore topics included current challenges in HEV epidemiology, emerging therapeutic strategies, and advances in the clinical management of HEV infections. The round table discussions fostered intensive interdisciplinary dialogue, identifying key knowledge gaps as potential avenues for collaborative research.

conclusionThis report summarises the data presented at the symposium and outlines the main themes and outcomes of the round table discussions, highlighting both the progress made and the future directions for HEV research.

Indexed as

Hepatitis EHepatitis E virusAntiviral AgentsCongresses as TopicHumansAntiviral Agentsantiviralshepatitis E virusneutralising antibodiesratHEV

Identifiers

PMID41104589
PMCPMC12532082

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.